Study S001240

A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

ClinicalTrials.gov record

Registration

Registration: NCT06391710
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 203
Start: 2024-05-06
Primary completion: 2026-01
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: DRUG:HRS9531; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) clinical summary score [From baseline (week 0) to week 36]
Change in body weight [From baseline (week 0) to week 36]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.